Vivus Submits NDA For Skin Spray To Treat Hot Flashs
This article was originally published in The Pink Sheet Daily
Executive Summary
EvaMist would be marketed as a more convenient form of hormone replacement than oral, gel and patch products.
You may also be interested in...
Vivus Sells EvaMist Rights To KV For $150 Million
Vivus CEO tells “The Pink Sheet” DAILY that sale of estrogen product will allow firm to focus on obesity candidate Qnexa.
Vivus Sells EvaMist Rights To KV For $150 Million
Vivus CEO tells “The Pink Sheet” DAILY that sale of estrogen product will allow firm to focus on obesity candidate Qnexa.
BioSante To Launch Hot Flash Drug Elestrin in 2007
Following FDA approval, the product is being positioned as the lowest dose of estradiol for moderate-to-severe hot flashes.